What Does It Mean When a Drug Is Approved?

It means a national regulator examined the evidence for one specific product, used one specific way, in one specific population, and judged that the benefits outweighed the risks for that use. Nothing wider than that. Approval is a narrow permission granted to a defined product for a defined purpose — not a general endorsement of a molecule, and not a ruling that a substance is safe, effective or worthwhile in the abstract.

The word is used far more loosely than it is granted. People say a compound is "approved" when what they mean is that some version of it, somewhere, for something, was cleared by somebody at some point. Every one of those vaguenesses matters, because every one of them marks a place where the approval stops applying.

What does a regulator actually assess?

Three things, kept deliberately separate: whether the product does what is claimed for the stated use, what harms it causes and at what rate, and whether it can be manufactured to a defined standard every single time. All three have to pass. A submission can fail on any one of them.

The first is narrower than it sounds. Not "is this compound beneficial" but "does this product, given this way, move this stated outcome, in this defined group, against a comparison group". The claim is written down in advance and judged on its own terms, not against the general enthusiasm surrounding the molecule.

The second is a catalogue rather than a verdict. Assessors want to know which adverse effects occurred, how often, how serious they were, who they happened to, and whether they were reversible. The output is a documented harm profile, not a declaration that harms are absent.

The third is the one people forget, and it is a large part of the assessment by sheer volume. Can this be made the same way, to the same specification, batch after batch? That covers the identity and purity of the active substance, the limits set on impurities, sterility where relevant, stability over shelf life, consistency of strength, and the documentation proving all of it. Arguments about medicines happen almost entirely on the first two questions, while much of the actual dossier is about whether the contents of the container reliably match what the trials tested. A compound with excellent results and a process that cannot be shown to produce consistent material is not approvable, because nothing links the two.

Is approval a statement about the molecule or the product?

The product. This is the single most useful thing to understand about the word, and almost every misuse of it comes from getting this backwards.

An approval attaches to a defined preparation: a named substance, at a defined strength, in a defined formulation, produced by a defined process at named facilities, tested against defined specifications, packaged and stored in defined conditions. Change enough of that and it is a different product needing its own assessment.

The reason is straightforward once stated. The evidence was generated with that product. The trials did not administer an abstract molecule; they administered real material of a particular purity, stability and potency, made under a particular process. The conclusion that benefits outweighed risks is a conclusion about the material that was actually given.

So the same molecule synthesised elsewhere, outside that oversight, has no share in the approval — not a partial share, not a presumptive one. It has never been assessed, its manufacturing has never been inspected against a specification, and no regulator has formed a view about it. This is the reasoning underneath the research-grade label, which we cover in a separate article on this site: material sold for laboratory use is not a cheaper edition of an approved medicine, because a large part of what approval assessed was the material itself.

Does approved mean safe?

No. It means the assessed benefits were judged to outweigh the assessed risks, for the stated use, in the population that was studied. Safety is not a box that gets ticked; it is one side of a comparison, and the comparison has a specific context.

Known harms are documented rather than absent. An approved product typically arrives with a long list of adverse effects attached to it, ranked by frequency, and that list is a sign the assessment worked rather than a sign something went wrong. A product with no documented harms usually means nobody looked systematically.

Because it is a comparison, tolerance shifts with what is at stake. Serious harms may be accepted for a treatment addressing a life-threatening condition with no alternative, while mild ones can be disqualifying for something intended for otherwise healthy people. The same harm profile can pass in one context and fail in another.

And the calculus can change with new data. Trials run after a product is in use can strengthen the case for it by demonstrating benefits on outcomes the original approval never claimed, cardiovascular outcome trials being the clearest recent example of a balance revisited upwards 1. The process runs the other way too: where compounds have been examined in populations they were not approved for, reviews have found modest or unclear benefits alongside a meaningful rate of adverse effects — a balance looking nothing like the one in the approved population 2.

Does approved for one thing mean useful for another?

No. An approval covers the stated use and nothing else, and a claim about a different use is simply outside it — however well established the product is for the use it was actually assessed for.

Use of an approved product outside its approved use — commonly called off-label use — does exist, and in many places qualified prescribers may do it. That is a clinical decision, made by a professional with responsibility for a particular patient. It is not an extension of the approval and is not evidence of one. Nothing here says when it is appropriate; that is not something an article can tell you.

What is worth noticing is how the gap gets used. A claim opens by establishing that a compound is approved, which is true, then moves to a use the approval never covered, which goes unaddressed. The join is rarely explicit. The two questions that close it: approved for what, and in whom?

The underlying evidence does not transfer either. A different use means a different population, often a different outcome measure, and a different balance — because both sides of it move at once. Benefits shown in people with a condition say little about people without it.

Why do approvals differ between countries?

Because regulators assess independently, and independent assessors looking at the same evidence can reach different conclusions. There is no single global authority whose decision the rest adopt.

Differences arise for ordinary reasons. Assessors can weigh the same outcome measure differently, or disagree about whether a trial's comparison was the right one, or take different views on how much residual uncertainty is acceptable. Local context enters too: what alternatives already exist, how common the condition is, how the health system will use the product. Timing matters as well, since applications are filed at different moments with different data behind them.

The practical consequence is that approval in one country is not recognition in another. A claim naming a country where a product is approved is a claim about that country only — and often no country is named at all, which is worth noticing whenever the word appears bare.

What does approval require in terms of evidence?

At the centre of it: randomised controlled trials in humans, with the outcomes to be measured declared before the data are collected 3. Everything else is supporting material around that core.

Randomisation exists to create a comparison group differing from the treated group only by chance and by the treatment. Without one there is no way to separate the effect of the product from the natural course of the condition, from who was selected to receive it, or from the general tendency of people in studies to improve.

Pre-specifying the endpoints matters just as much, for a less obvious reason. Measure enough things in enough ways and something will move; choosing which result to feature after seeing the data converts noise into a finding. Declaring the primary outcome, the analysis and the population in advance removes that choice, which is why reporting standards for randomised trials weigh it so heavily and ask authors to state plainly what was pre-specified and what was not 3.

The shape a regulator looks for is therefore consistent: a trial large enough that chance is not a plausible explanation, with a defined comparison, a primary endpoint fixed in advance, blinding where possible, and full publication so other researchers can attack it. Large placebo-controlled trials with pre-specified primary endpoints are the standard example 4.

The bar is high because the cost of being wrong is asymmetric. A treatment cleared for general use may be given to very large numbers of people over many years, including people unlike anyone in the trials. Weaker designs — uncontrolled case series, before-and-after comparisons — reliably produce positive-looking results whether or not the treatment does anything.

What is not approval?

Most of what gets presented as evidence of approval is something else entirely. This list is short and worth committing to memory, because recognising these is the practical skill:

• A published study. Publication means a journal accepted a report of an experiment. It is a contribution to a conversation, not a decision, and no regulator has necessarily read it.
• A patent. A property right granted on novelty, examined by an office that assesses neither effectiveness nor safety. Patents are routinely granted for things that never work.
• An approval in one country, cited as though universal. Approval is national; without the country and the use, the word carries almost no information.
• A certificate of analysis. A test report on a sample or batch, usually produced by or for the seller. At best it says something about one container.
• Wide availability. That something is sold in many places reflects demand and supply chains. Availability and assessment are separate facts and frequently diverge.
• A registered or ongoing clinical trial. Registration means somebody declared an intention to run a study. It is a plan, not a result.
• The approval of a different product containing the same molecule — the central point of this article restated.

Faced with the word in a claim, five questions resolve it: which product exactly, for which use, in which population, in which country, and according to whom. Claims that can answer all five are usually accurate. Claims that can answer none are generally not making a regulatory statement at all — they are borrowing the authority of one.

So what does approved actually mean?

It means that one product, made one way, was assessed by one country's regulator for one stated use in one studied population, and that the benefits were judged to outweigh the known risks for that use, on the evidence available at the time.

Nearly everything the word is asked to carry in conversation sits outside that sentence. It is not a statement that a molecule is good, nor a guarantee of safety, nor transferable to other uses, groups, countries or manufacturers. And it is not permanent, because the balance it records can be revisited when new evidence arrives.

None of which makes approval unimportant — quite the opposite. It remains the most demanding independent review most treatments ever face, and the fact that someone outside the company read the full evidence package and could have said no is worth a great deal. The point is to read the word as what it is: a narrow, specific, revisable permission for one product used one way. Read that way it is genuinely informative. Read as a general endorsement, it is one of the most misleading words in the subject.